Serabelisib

Phase 2Small molecule

FFaeth Therapeutics

Serabelisib is one of 104 small molecule programs targeting Breast Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

103

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CarcinomaRecruiting

Endometrial CancerRecruiting

Breast CarcinomaPreclinical

Recruiting

Endometrial CancerPhase 2

Recruiting

Competition

Competitive Landscape

103 competitors in Endometrial Cancer

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

53 2

Keytruda

Merck & Co.

Phase 3

21 3

Femara

Novartis

Phase 3

18 4

Paraplatin

AAvyxa

Phase 3

37 5

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

27 6

Megace

Bristol-Myers Squibb

Phase 3

10 7

Lenvima

Eisai

Phase 3

6 8

Lynparza

AstraZeneca

Phase 3

6 9

Tecentriq

Roche

Phase 3

4 10

Depo-Provera

Eli Lilly

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 2Recruiting

Endometrial Cancer

NCT06463028

Q2 2033

PreclinicalRecruiting

Breast Carcinoma

NCT07558733

Clinical

Trials by Indication[1]

Endometrial Cancer1 trial

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

Recruiting·FFaeth Therapeutics·Phase 2·NCT06463028·40 enrolled

Advanced Solid Tumors1 trial

Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations

Completed·FFaeth Therapeutics·Phase 1·NCT05300048·34 enrolled

Patients With Advanced Solid Tumors1 trial

A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors

Unknown status·PPetra Pharma·Phase 1/2·NCT04073680·60 enrolled

Breast Carcinoma1 trial

Open-Label Umbrella Study to Evaluate Safety and Efficacy of Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced or Metastatic Breast Cancer

Recruiting·FFaeth Therapeutics·Preclinical·NCT07558733·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Serabelisib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Serabelisib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Serabelisib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Faeth Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: FFaeth Therapeutics

Serabelisib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Q2 2033

Trials by Indication[1]

Endometrial Cancer1 trial

Advanced Solid Tumors1 trial

Patients With Advanced Solid Tumors1 trial

Breast Carcinoma1 trial

References

Drug Info

Quick Facts

Related News